- Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
- Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
- Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
- Merrimack Receives $225 Million Milestone Payment from Ipsen
- Merrimack Reports Full Year 2023 Financial Results
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
More ▼
Key statistics
On Friday, Merrimack Pharmaceuticals Inc (MACK:NMQ) closed at 15.12, -4.85% below its 52-week high of 15.89, set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.08 |
---|---|
High | 15.13 |
Low | 15.08 |
Bid | 15.11 |
Offer | 15.14 |
Previous close | 15.07 |
Average volume | 257.34k |
---|---|
Shares outstanding | 14.53m |
Free float | 14.36m |
P/E (TTM) | -- |
Market cap | 218.99m USD |
EPS (TTM) | -0.0826 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼